indacaterol

Known as: 5-(2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2017
0204020002017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
BACKGROUND Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting… (More)
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND We compared the efficacy and safety of indacaterol and tiotropium in patients with severe chronic obstructive… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
We investigated the efficacy and safety of dual bronchodilation with QVA149 versus its monocomponents indacaterol and… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Current guidelines recommend treatment with one or more long-acting bronchodilators for patients with moderate or more… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β(2)-agonist bronchodilator recently approved in Europe for the… (More)
  • table 1
  • table 2
  • figure 2
  • figure 1
  • table 3
Is this relevant?
2011
2011
Indacaterol is a novel, inhaled once-daily ultra long-acting β2-agonist for the treatment of COPD. This randomised, double-blind… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2011
2011
PURPOSE Pooled data were analyzed to evaluate the safety and tolerability of indacaterol, a once-daily inhaled long-acting β(2… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2011
2011
PURPOSE As COPD patients commonly suffer cardio- and cerebrovascular (CCV) co-morbidities, our purpose was to establish the CCV… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
RATIONALE Indacaterol is the first once-daily, long-acting inhaled beta(2)-agonist bronchodilator studied in patients with… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Indacaterol is a long-acting inhaled beta(2)-agonist (LABA) for the treatment of chronic obstructive pulmonary disease… (More)
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 2
Is this relevant?